

# **Global Bladder Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023**

<https://marketpublishers.com/r/G221357BCA8EN.html>

Date: November 2017

Pages: 218

Price: US\$ 4,400.00 (Single User License)

ID: G221357BCA8EN

## **Abstracts**

Global Bladder Cancer Treatment Market:

Global bladder cancer treatment market estimated to be valued US\$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for bladder cancer treatment is projected to reach US\$ XX Mn by 2023.

Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma.

Increase in incidence rate of bladder cancer cases, technological advancements, drug innovations with regard to the treatment of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer treatment drugs. In addition, the rise in awareness about bladder diseases, their available therapies in the market, and increase in health care expenditure are driving the global market for bladder cancer treatment drugs. However, the rise in a number of patent expirations, asymptomatic nature of the disease, and rise in the use of generic drugs are some of the major factors restraining the revenue growth of the global bladder cancer treatment drugs market over the forecast period.

Global bladder cancer treatment market is segmented based on cancer type, drug

class, and distribution channel:

Based on cancer type, global bladder cancer treatment market is segmented as:

Transitional cell bladder cancer

Invasive bladder cancer

Superficial bladder cancer

Squamous cell bladder cancer

Other rare types

Based on drug class, global bladder cancer treatment market is segmented as:

Chemotherapy

Alkylating agents

Plant alkaloids

Taxanes

Anti-tumour Antibiotics

Anti-metabolites

Topoisomerase inhibitors

Immunotherapy

Tumor-targeting mAbs

DC-Based immunotherapy

Peptide- and DNA-based anticancer vaccines

Immune stimulatory cytokines

Immune modulatory mAbs

Immuno suppressive metabolism Inhibitors

Pattern recognition receptor Agonists

Others

Based on distribution channel, global bladder cancer treatment market is segmented as:

Hospital Pharmacies

Retail Pharmacies

Others

As per to the National Institute of Health, approximately 17,000 women and 45,000 men for every year are diagnosed with the bladder cancer in U.S. only. Market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally. As per to The American Cancer Society, in 2017, estimated bladder cancers in the United States were 79,030 new cases (about 60,490 in men and 18,540 in women) were diagnosed and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women). Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. Increasing number of mergers and acquisitions, the rise in a number of collaborations and partnerships, new product launches and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.

Global bladder cancer treatment market is segmented into five regions: North America, Europe, Asia Pacific, Latin America and The Middle East & Africa. North America followed by Europe, comprise largest market share for the bladder cancer treatment

market due to the availability of advanced health care solutions, increase in the bladder cancer cases, rise in concern about bladder problems and development of health care infrastructure in the region. Asia is expected to show a high growth rate in the bladder cancer treatment drugs market during the forecast period due to rise in significant growth in bladder cancer cases, rise in need for the improved bladder cancer treatments and therapies, increasing awareness on cancer diagnosis. Growing demographics and economies in the developing countries, such as India and China, are anticipated to rise the bladder cancer treatment drugs market in Asia-Pacific region.

Some of the players in the global bladder cancer treatment market include AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Co., F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), and Sanofi (France)

In 2017, AstraZeneca received U.S. FDA accelerated approval for Imfinzi (Durvalumab) for the treatment of bladder cancer

In 2016, FDA has granted Biologic License Application and priority review of Roche's Atezolizumab for the treatment of advanced bladder cancer

## **REPORT OUTLINE:**

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL BLADDER CANCER TREATMENT MARKET INTRODUCTION**

2.1. Global Bladder Cancer Treatment Market– Taxonomy

2.2. Global Bladder Cancer Treatment Market–Definitions

2.2.1. Drug Class

2.2.2. Cancer Type

### **3. GLOBAL BLADDER CANCER TREATMENT MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Bladder Cancer Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Bladder Cancer Treatment Market– Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.7. Global Bladder Cancer Treatment Market– Recent Product Launches

### **4. GLOBAL BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL BLADDER CANCER TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023**

5.1. Chemotherapeutic Agents (Alkylating agents, Plant alkaloids, Taxanes, Anti-tumour Antibiotics, Anti-metabolites, and Topoisomerase inhibitors)

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Immunotherapy (Tumor-targeting mAbs, DC-Based immunotherapy, Peptide- and DNA-based anticancer vaccines, Immune stimulatory cytokines, Immunomodulatory mAbs, and Others)

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

## **6. GLOBAL BLADDER CANCER TREATMENT MARKET FORECAST, BY CANCER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

6.1. Transitional Cell Bladder Cancer

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Invasive Bladder Cancer

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Superficial Bladder Cancer

6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Squamous Cell Bladder Cancer

6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

6.5. Other Rare Types

6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3. Market Opportunity Analysis

## **7. GLOBAL BLADDER CANCER TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023**

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

#### 7.3. Others

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

## **8. GLOBAL BLADDER CANCER TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

### 8.2. Europe

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.2.3. Market Opportunity Analysis

### 8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.3.3. Market Opportunity Analysis

### 8.4. Latin America

- 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.4.3. Market Opportunity Analysis

### 8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.5.3. Market Opportunity Analysis

### 8.6. Global Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2017 – 2023

## **9. NORTH AMERICA BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 9.1.1.1. Chemotherapy
  - 9.1.1.1.1. Alkylating agents
  - 9.1.1.1.2. Plant alkaloids
  - 9.1.1.1.3. Taxanes
  - 9.1.1.1.4. Anti-tumour Antibiotics
  - 9.1.1.1.5. Anti-metabolites
  - 9.1.1.1.6. Topoisomerase inhibitors
- 9.1.1.2. Immunotherapy
  - 9.1.1.2.1. Tumor-targeting mAbs
  - 9.1.1.2.2. DC-Based immunotherapy
  - 9.1.1.2.3. Peptide- and DNA-based anticancer vaccines
  - 9.1.1.2.4. Immune stimulatory cytokines
  - 9.1.1.2.5. Immune modulatory mAbs
  - 9.1.1.2.6. Immuno suppressive metabolism Inhibitors
  - 9.1.1.2.7. Pattern recognition receptor Agonists
  - 9.1.1.2.8. Others
- 9.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 9.1.2.1. Transitional cell bladder cancer
  - 9.1.2.2. Invasive bladder cancer
  - 9.1.2.3. Superficial bladder cancer
  - 9.1.2.4. Squamous cell bladder cancer
  - 9.1.2.5. Other rare types
- 9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 9.1.3.1. Hospital Pharmacies
  - 9.1.3.2. Retail Pharmacies
  - 9.1.3.3. Others
- 9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  - 9.1.4.1. U.S.
  - 9.1.4.2. Canada
- 9.1.5. North America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
- 9.1.6. North America Bladder Cancer Treatment Market Dynamics – Trends

## **10. EUROPE BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**



### 10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

#### 10.1.1.1. Chemotherapy

10.1.1.1.1. Alkylating agents

10.1.1.1.2. Plant alkaloids

10.1.1.1.3. Taxanes

10.1.1.1.4. Anti-tumour Antibiotics

10.1.1.1.5. Anti-metabolites

10.1.1.1.6. Topoisomerase inhibitors

#### 10.1.1.2. Immunotherapy

10.1.1.2.1. Tumor-targeting mAbs

10.1.1.2.2. DC-Based immunotherapy

10.1.1.2.3. Peptide- and DNA-based anticancer vaccines

10.1.1.2.4. Immune stimulatory cytokines

10.1.1.2.5. Immune modulatory mAbs

10.1.1.2.6. Immuno suppressive metabolism Inhibitors

10.1.1.2.7. Pattern recognition receptor Agonists

10.1.1.2.8. Others

### 10.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Transitional cell bladder cancer

10.1.2.2. Invasive bladder cancer

10.1.2.3. Superficial bladder cancer

10.1.2.4. Squamous cell bladder cancer

10.1.2.5. Other rare types

### 10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospital Pharmacies

10.1.3.2. Retail Pharmacies

10.1.3.3. Others

### 10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

10.1.6. Europe Bladder Cancer Treatment Market Dynamics – Trends

## **11. ASIA-PACIFIC BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Chemotherapy

11.1.1.1.1. Alkylating agents

11.1.1.1.2. Plant alkaloids

11.1.1.1.3. Taxanes

11.1.1.1.4. Anti-tumour Antibiotics

11.1.1.1.5. Anti-metabolites

11.1.1.1.6. Topoisomerase inhibitors

11.1.1.2. Immunotherapy

11.1.1.2.1. Tumor-targeting mAbs

11.1.1.2.2. DC-Based immunotherapy

11.1.1.2.3. Peptide- and DNA-based anticancer vaccines

11.1.1.2.4. Immune stimulatory cytokines

11.1.1.2.5. Immune modulatory mAbs

11.1.1.2.6. Immuno suppressive metabolism Inhibitors

11.1.1.2.7. Pattern recognition receptor Agonists

11.1.1.2.8. Others

11.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Transitional cell bladder cancer

11.1.2.2. Invasive bladder cancer

11.1.2.3. Superficial bladder cancer

11.1.2.4. Squamous cell bladder cancer

11.1.2.5. Other rare types

11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospital Pharmacies

11.1.3.2. Retail Pharmacies

11.1.3.3. Others

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD

Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Bladder Cancer Treatment Market- Opportunity Analysis Index -  
By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

11.1.6. Asia-Pacific Bladder Cancer Treatment Market Dynamics – Trends

## **12. LATIN AMERICA BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue  
(USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Chemotherapy

12.1.1.1.1. Alkylating agents

12.1.1.1.2. Plant alkaloids

12.1.1.1.3. Taxanes

12.1.1.1.4. Anti-tumour Antibiotics

12.1.1.1.5. Anti-metabolites

12.1.1.1.6. Topoisomerase inhibitors

12.1.1.2. Immunotherapy

12.1.1.2.1. Tumor-targeting mAbs

12.1.1.2.2. DC-Based immunotherapy

12.1.1.2.3. Peptide- and DNA-based anticancer vaccines

12.1.1.2.4. Immune stimulatory cytokines

12.1.1.2.5. Immune modulatory mAbs

12.1.1.2.6. Immuno suppressive metabolism Inhibitors

12.1.1.2.7. Pattern recognition receptor Agonists

12.1.1.2.8. Others

12.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue  
(USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Transitional cell bladder cancer

12.1.2.2. Invasive bladder cancer

12.1.2.3. Superficial bladder cancer

12.1.2.4. Squamous cell bladder cancer

12.1.2.5. Other rare types

12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospital Pharmacies

12.1.3.2. Retail Pharmacies

12.1.3.3. Others

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

12.1.6. Latin America Bladder Cancer Treatment Market Dynamics – Trends

### **13. MIDDLE EAST & AFRICA BLADDER CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Chemotherapy

13.1.1.1.1. Alkylating agents

13.1.1.1.2. Plant alkaloids

13.1.1.1.3. Taxanes

13.1.1.1.4. Anti-tumour Antibiotics

13.1.1.1.5. Anti-metabolites

13.1.1.1.6. Topoisomerase inhibitors

13.1.1.2. Immunotherapy

13.1.1.2.1. Tumor-targeting mAbs

13.1.1.2.2. DC-Based immunotherapy

13.1.1.2.3. Peptide- and DNA-based anticancer vaccines

13.1.1.2.4. Immune stimulatory cytokines

13.1.1.2.5. Immune modulatory mAbs

13.1.1.2.6. Immuno suppressive metabolism Inhibitors

13.1.1.2.7. Pattern recognition receptor Agonists

13.1.1.2.8. Others

13.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Transitional cell bladder cancer

13.1.2.2. Invasive bladder cancer

13.1.2.3. Superficial bladder cancer

13.1.2.4. Squamous cell bladder cancer

13.1.2.5. Other rare types

13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospital Pharmacies

13.1.3.2. Retail Pharmacies

13.1.3.3. Others

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Bladder Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

13.1.6. MEA Bladder Cancer Treatment Market Dynamics – Trends

## **14. COMPETITION LANDSCAPE**

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. AstraZeneca plc (U.K.)

14.2.2. Bristol-Myers Squibb (U.S.)

14.2.3. Celgene Corporation (U.S.)

14.2.4. Eli Lilly and Company (U.S.)

14.2.5. F. Hoffmann-La Roche (Switzerland)

14.2.6. GlaxoSmithKline plc (U.K.)

14.2.7. Novartis AG (Switzerland)

14.2.8. Pfizer Inc. (U.S.)

14.2.9. Sanofi (France)

## **15. RESEARCH METHODOLOGY**

## **16. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Global Bladder Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G221357BCA8EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G221357BCA8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

